Reported Earlier, CG Oncology Prices $204.4M Public Offering Of 8M Common Shares At $28/Share
Reported Earlier, CG Oncology Prices $204.4M Public Offering Of 8M Common Shares At $28/Share
CG Oncology, Inc. (NASDAQ:CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer, today announced the pricing of its public offering of 8,000,000 shares of its common stock, 7,300,000 of which are being offered by CG Oncology and 700,000 of which are being offered by an existing stockholder of CG Oncology, each at a public offering price of $28.00 per share. The gross proceeds to CG Oncology from the offering, before deducting underwriting discounts and commissions and other offering expenses, are expected to be $204.4 million
CG Oncology, Inc.（納斯達克：CGON）是一家處於後期臨床階段的生物製藥公司，專注於開發和商業化一種潛在的可替代膀胱保存治療方案，旨在幫助患有膀胱癌的患者。今天，公司宣佈其公開發行的8,000,000股普通股的定價，其中7,300,000股由CG Oncology提供，700,000股由CG Oncology的一位現有股東提供，公開發行價格爲每股28.00美元。CG Oncology從此次發行中獲得的總收益爲20440萬，在扣除承銷折扣、佣金和其他發行費用之前。
譯文內容由第三人軟體翻譯。
